{"id":"ecadf213a69e","type":"article","url":"https://hartvaat.nl/2018/05/15/liraglutide-bij-diabetes-type-2-met-polyvasculaire-ziekte-leader-analyse/","title":"Liraglutide bij diabetes type 2 met polyvasculaire ziekte: LEADER-analyse","title_en":"Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial.","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["diabetes-type-2"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.118.033898","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.118.033898","authors":["Subodh Verma","Deepak L Bhatt","Stephen C Bain","John B Buse","Johannes F E Mann","Steven P Marso","Michael A Nauck","Neil R Poulter","Richard E Pratley","Bernard Zinman","Marie M Michelsen","Tea Monk Fries","Søren Rasmussen","Lawrence A Leiter"],"significance":7,"published":"2018-05-15","source_date":"2018-05-15","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"This LEADER subanalysis in patients with polyvascular disease showed that liraglutide reduces cardiovascular events even in the highest-risk diabetic patients with multiple vascular territories affected, supporting GLP-1 agonist use across the cardiovascular risk spectrum.","created":"2026-07-03T10:27:17Z","updated":"2026-07-03T13:26:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"LEADER subanalyse bij patiënten met polyvasculaire ziekte — de hoogste risicogroep. Liraglutide vermindert CV-events ook bij uitgebreid vaatlijden.","abstract_original":""}